Heart drug dobutamine put to the test in rare amyloid heart disease
NCT ID NCT06318260
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is studying how the drug dobutamine affects the heart in 15 people with a rare condition called wild-type transthyretin amyloid cardiomyopathy (ATTRwt). Participants will receive increasing doses of dobutamine while doctors measure heart function using ultrasound and a catheter. The goal is to see how the drug changes blood flow and heart pressures, and to check for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Dobutamine (Dobutrex)
What this could lead to
If successful, this could help doctors understand whether dobutamine can safely improve heart function in people with this type of heart disease.
What could go wrong
This is a very small, early-phase study with only 15 participants. It is designed to measure short-term effects, not to prove long-term benefit or safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATTR AMYLOIDOSIS WILD TYPE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Department of Cardiology, Aarhus University Hospital
RECRUITINGAarhus, 8200, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••